Clinical Trial Update: Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

A Phase 2 study assessing BIIL 284 BS for improving exercise endurance in chronic obstructive pulmonary disease has been completed. The sponsor was Boehringer I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BIIL 284 BS

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED